First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

被引：0
作者：
Ang, J. E. [1 ]
Hauns, B. [2 ]
Mais, A. [2 ]
Parker, A. [1 ]
Lal, R. [1 ]
Olmos, D. [1 ]
Mollenhauer, M. [2 ]
Walz, A. [2 ]
de Bono, J. S. [1 ]
机构：
[1] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[2] Nycomed GmbH, Exploratory Clin Dev, Constance, Germany
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72327-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / 124
页数：2
相关论文
共 50 条
  • [21] Lung cancer: First-in-man phase I trial with lorlatinib
    Romero D.
    Nature Reviews Clinical Oncology, 2018, 15 (1) : 7 - 7
  • [22] Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Ramalingam, Suresh S.
    Parise, Robert A.
    Ramananthan, Ramesh K.
    Lagattuta, Theodore F.
    Musguire, Lori A.
    Stoller, Ronald G.
    Potter, Douglas M.
    Argiris, Athanassios E.
    Zwiebel, James A.
    Egorin, Merrill J.
    Belani, Chandra P.
    CLINICAL CANCER RESEARCH, 2007, 13 (12) : 3605 - 3610
  • [23] First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Yan, Li
    Patnaik, Amita
    Fearen, Ivy
    Olmos, David
    Papadopoulos, Kyriakos
    Baird, Richard D.
    Delgado, Liliana
    Taylor, Adekemi
    Lupinacci, Lisa
    Riisnaes, Ruth
    Pope, Lorna L.
    Heaton, Simon P.
    Thomas, George
    Garrett, Michelle D.
    Sullivan, Daniel M.
    de Bono, Johann S.
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4688 - 4695
  • [24] A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors
    Brunetto, A. T.
    Ang, J. E.
    Lal, R.
    Olmos, D.
    Frentzas, S.
    Mais, A.
    Hauns, B.
    Mollenhauer, M.
    Lahu, G.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Kelly, W
    O'Connor, O
    Richon, VM
    Tong, W
    Rao, TD
    Chiao, J
    O'Brien, JP
    Rifkid, RA
    Marks, PA
    Scher, HI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S88 - S88
  • [26] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [27] Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
    Wainberg, Zev A.
    de Bono, Johann S.
    Mina, Lida
    Sachdev, Jasgit
    Byers, Lauren Averett
    Chugh, Rashmi
    Zhang, Charlie
    Henshaw, Joshua W.
    Dorr, Andrew
    Glaspy, John
    Ramanathan, Ramesh
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [28] Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor
    Donovan, EA
    Ryan, Q
    Acharya, M
    Chung, E
    Trepel, J
    Maynard, K
    Sausville, E
    Murgo, A
    Melillo, G
    Conley, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 215S - 215S
  • [29] Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
    Watanabe, Takashi
    Kato, Harumi
    Kobayashi, Yukio
    Yamasaki, Satoshi
    Morita-Hoshi, Yuriko
    Yokoyama, Hiroki
    Morishima, Yasuo
    Ricker, Justin L.
    Otsuki, Tetsuya
    Miyagi-Maesima, Akiko
    Matsuno, Yoshihiro
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (01) : 196 - 200
  • [30] Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers
    Piekarz, R.
    Luchenko, V.
    Draper, D.
    Wright, J. J.
    Figg, W. D.
    Fojo, A. T.
    Bates, S. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345